Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic Hyperplasia patients

Journal of Cancer

Volumn 5, Issue 3, 2014, Pages 182-191

  Haj Ahmad, Taha A ^a   Abdalla, Moemen A K ^b   Haj Ahmad, Yousef ^a  

^a BROCK UNIVERSITY   (Canada)

^b Alexandria University Faculty Of Science   (Egypt)

Author keywords

Benign prostatic hyperplasia; Biomarkers; MicroRNA; Prostate cancer; Urine

Indexed keywords

MICRORNA; MICRORNA 1234; MICRORNA 1238; MICRORNA 1825; MICRORNA 191; MICRORNA 1913; MICRORNA 451; MICRORNA 484; MICRORNA 486 3P; MICRORNA 486 5P; MICRORNA 563; MICRORNA 625; MICRORNA 92A; MICRORNA 92B; MICRORNA 940; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; EXPLORATORY RESEARCH; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UPREGULATION;

EID: 84896958900     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6799     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: Cancer J Clin 2011; 61: 69-90.
2. [Internet] Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), Nat Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/.
3. Boyle P, Severi G and Giles GG. The epidemiology of prostate cancer. Urology Clin North Am. 2003; 30: 209-217.
4. Yin M, Bastacky S, Chandran U, Becich MJ and Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. The J of Urology 2008; 179: 892-895.
5. Dunn JE. Cancer epidemiology in populations of the United States-with emphasis on Hawaii and California-and Japan. Cancer Res. 1975; 35(11 Pt. 2): 3240-3245.
6. Mettlin C, Lee F, Drago J and Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949-2958.
7. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate- specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
8. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. The J of the American Med Association. 1992; 267(16): 2215-2220.
9. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine EE. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909-916.
10. Rao AR, Motiwala HG and Karim OM. The discovery of prostate- specific antigen. BJU Int 2008; 101: 5-10.
11. Woolf SH. The accuracy and effectiveness of routine population screening with mammography, prostate specific antigen, and prenatal ultrasound: a review of published scientific evidence. Int J Technol Assess Health Care 2001; 3: 275-304.
12. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC and Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract. 2002; 3: 19.
13. Oh WK, Hurwitz M, Richie JP, D'Amico AV and Kantoff PW. Neoplasms of the Prostate. In: Kufe DW, et al, editors. Cancer Medicine. Hamilton, Canada: BC Decker Inc. 2003.
14. Chou R, Jennifer MC, Tracy D, Christina B, Ian B, Rongwei F, Ken G, Helen CK, Clarence L, Ashley MJ, Bruin R and Kenneth L. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Annals of internal medicine. 2011; 155(11): 762-771.
15. Pisitkun T, Johnstone R and Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics 2006; 5: 1760-1771.
16. Truong M, Yang B, Jarrard D. Towards the Detection of Prostate Cancer in Urine: a Critical Analysis. The J of Urology. 2012; PrePub.
17. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2): 215-233.
18. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007; 6: 60-66.
19. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
20. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM and Harris CC. Unique microRNA signature in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
21. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA., Downing JR, Jacks T, Horvitz HR and Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
22. Zhang B, Pan X, Cobbv GP and Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302: 1-12.
23. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798.
24. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev. 2006; 16: 4-9.
25. Calin GA, Sevignani C, Dan Dumitru C, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Nal Acad Sci USA. 2004; 101: 2999-3004.
26. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. (2007). The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007; 67(16): 7713-7722.
27. Coppola V, De Maria R, and Bonci D. MicroRNAs and prostate cancer. Endocrine- Related Cancer. 2010;17(1): F1-F17.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4): 402-408.
29. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34: D140-D144.
30. Chen H, Pong RC, Wang Z, Hsieh JT. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 2002; 79: 573-581.
31. Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic regulation of a novel tumour suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem. 2003; 278: 3121-3130.
32. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem. 2002; 277: 12622-12631.
33. Zeller C, Hinzmann B, Seitz S, Prokoph H, Burkhard-Goettges E, Fischer J, Jandrig B, Schwarz LE, Rosenthal A, Scherneck S.SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer. Oncogene 2003; 22: 2972-2983.
34. Nerlich AG, Wiest I, Wagner E, Sauer U, Schleicher ED. Gene expression and protein deposition of major basement membrane components and TGF-beta 1 in human breast cancer. Anticancer Res. 1997; 17(6D): 4443-4449.
35. Palmer DH, Hussain SA, Ganesan R, Cooke PW, Wallace DM, Young LS, James ND. CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule. Oncology reports. 2004 ;12(4): 679-682.
36. Weiner HL, Huang H, Zagzag D, Boyce H, Lichtenbaum R, Ziff EB. Consistent and selective expression of the discoidin domain receptor-1 tyrosine kinase in human brain tumors. Neurosurgery. 2000; 47: 1400-1409.
37. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-1203.
38. Yang SH, Baek HA, Lee HJ, Park HS, Jang KY, Kang MJ, Lee DG, Lee YC, Moon WS, Chung MJ. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep. 2010; 24(2): 311-319.
39. Clancy JL, Henderson MJ, Russell AJ, Anderson DW, Bova RJ, Campbell IG, Choong DY, Macdonald GA, Mann GJ, Nolan T, Brady G, Olopade OI, Woollatt E, Davies MJ, Segara D, Hacker NF, Henshall SM, Sutherland RL, Watts CK. EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene 2003; 22: 5070-5081.
40. Diwadkar-Navsariwala V, Prins GS, Swanson SM, Birch LA, Ray VH, Hedayat S, Lantvit DL, Diamond AM. Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proceedings of the Nal Academy of Sciences of the United States of America. 2006; 103(21): 8179-8184.
41. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews: Genetics. 2004; 5(7): 522-531.
42. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W and Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr biol. 2002; 12(9): 735-739.
43. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Bälter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Grönberg H, Xu J, Carpten JD. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Nat Cancer Inst. 2007; 99(24): 1836-1844.
44. Sasaki T, Costell M, Mann K, Timpl R. Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity. FEBS Lett. 1998; 435(2-3): 169-172.
45. Bengtsson E, Mörgelin M, Sasaki T, Timpl R, Heinegard D, Aspberg A. The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor. J Biol Chem. 2002; 277(17): 15061-15068.
46. Henderson MJ, Munoz MA, Saunders DN, Clancy JL, Russell AJ, Williams B, Pappin D, Khanna KK, Jackson SP, Sutherland RL, Watts CK. EDD Mediates DNA Damage-induced Activation of CHK2. J. Biol. Chem. 2006; 281: 39990-40000.
47. Shariat SF and Roehrborn CG. Using biopsy to detect prostate cancer. Reviews in Urology. 2008; 10(4): 262-280.
48. Presti JC. Prostate biopsy: current status and limitations. Reviews in Urology. 2007; 9(3): 93-98.